1Helen CJ,Noel RZ,Wang M,et al.Management of influenza use of new antivirals and resistance in perspective.Clin Drug Invest,2000,20: 447-454.
2Libow LS,Neafeld RR,Olson E,et al.Sequential outbreak of influenza A and B in nursing home: efficacy of vaccine and amantadine.J Am Geriatr Soc,1996,44: 1153-1157.
3Hayden FG.Antivirals for pandemic influenza.J Infect Dis,1997,176 Suppl 1:s56-s61.
4Douglas RGJ.Prophylaxis and treatment of influenza.N Eng J Med,1990,322: 443-450.
5Keysor LA,Karl M,Nafziger AN,et al.Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.Arch Intern Med,2000,160:1485.
6Hayden FG.Amantadine and rimantadine-clinical aspects.In: Richman DD,ed.Antiviral drug resistance.Chishester,England: John wiley,1996.59-77.
7Lin C,Eichelberger MC,Compans RW,et al.Influenza type A virus neuraminidase dose not play a role in viral entry,replication,assembly,or budcling.J Virol,1995,69: 1099-1106.
8Hayden FG,Treanor JJ,Betts RF,et al.Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.JAMA,1996,275: 295-299.
9Hayden FG,Treanor JJ,Fritz RS,et al.Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza.Randomized controlled trials for prevention and treatment.JAMA,1999,282: 1240-1246.
10Calfee DP,Hayden FG.New approaches to influenza chemotherapy: neuraminidase inhibitors.Drugs,1998,56: 537-553.
